Banner Desktop 960 x 350_41

High-Throughput ADME Services

Capabilities that accelerate preclinical studies

In vitro ADME screening during the lead optimization stage of drug discovery positively impacts drug candidate selection with an enhanced probability of success in clinical trials. Since most new drug candidates fail during preclinical and clinical development, and the late stage of the drug development cycle can be a lengthy and costly process, any means of identifying drug candidates with optimized ADME and pharmacokinetics properties in the discovery stage will have a significant impact on the drug discovery process overall.

Q2 Solutions’ highly automated in vitro ADME laboratory partners with small, mid and large pharmaceutical customers around the world to perform large scale ADME screening assays using in-house or client-customized protocols. Our rapid ADME assay development turnaround time enables parallel optimization of the ADME properties of your chemical platform, alongside your potency and selectivity targets, thereby enabling you to make important decisions about your potential candidates.

Partner with us for your preclinical ADME screening needs to realize:

  • Increased Speed: Establishment of high-throughput ADME assays allows for the prioritization of your drug candidates by their ADME properties in parallel with optimization of their efficacy at early discovery phases. This approach improves the overall quality of your drug candidates and the probability of their success, thereby shortening the drug discovery and development process.
  • Reduced Cost and Development Cycle Times: We generate in vitro screening data that customers can use in their in-silico models. This combination of in vitro screening and in-silico alternatives helps customers generate ADME data that can lead to a reduction in animal studies, and a more efficient and potentially less expensive study.
  • Optimized Discovery Cycle Time: By ensuring that only the most promising candidates are progressed through to clinical trials, the drug discovery pipeline can become more streamlined and efficient once clinical trials begin. Optimizing drug leads early on reduces the cost and time of progressing unsuccessful compounds through to the later stages of development.
  • Detailed Dose Levels: Pharmacokinetic (PK) parameters are extrapolated from measurement of drug concentration in the plasma, blood, or other biological matrices over a selected time period. This provides information that can guide your future animal and clinical studies for the selection of the dose levels and frequency of administration.

Our experienced scientists perform a range of high-throughput screening services, routinely conducting industry-standard in vitro ADME assays and continuously developing novel in vitro assays to address current metabolism issues and the evolving needs of our customers.


The initiation of early ADME screening dramatically decreases the proportion of compounds failing in clinical trials. Our preclinical ADME screening services help customers eliminate weak drug candidates prior to clinical development, thereby helping them to focus their resources on potential drug candidates so that the right drugs get to the right patients faster and more efficiently.

Capacity and on-time delivery is critical to this process.


Related Services & Solutions

Bioanalytical and ADME assays and services list Bioanalytical and ADME assays and services list

Related Thought Leaders Insights

Factsheet Small Molecule Bioanalytical and ADME Solutions
Q2 Solutions offers tailored and comprehensive small molecule bioanalytical and ADME laboratory services. We combine scientific excellence, high-quality project management, and outstanding delivery...
Scientific Poster Quantification of the Polydisperse Heparin Analog Dociparstat by Signature Disaccharide Analysis in the Presence of Concomitant Enoxaparin Dosing in Support of a Phase 2/3 Study in Patients with Severe COVID-19
Analysis of a polydisperse heparin analog therapeutic (CX-01, Dociparstat) was conducted in human plasma by signature disaccharide (NS6S) analysis, with NS6S being unique to CX-01 in native human...
Podcast Hybrid assays: an interview with Barry Jones and Adriane Spytko
In this podcast Barry Jones (Director, LC–MS Biologics and Biomarkers at Q² Solutions) and Adriane Spytko (Manager, LC–MS Biologics at Q² Solutions; both NY, USA) discuss hybrid assays using both...